Expanded Access Intermediate Size Treatment Protocol: Pritelivir for Immunocompromised Subjects With Treatment Resistant Herpes Simplex Virus Type 1 or 2
Condition:   HSV Intervention:   Drug: Pritelivir Sponsors:   AiCuris Anti-infective Cures AG;   Impatients N.V. trading as myTomorrows Available (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 6, 2023 Category: Research Source Type: clinical trials

A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer
Conditions:   Head and Neck Cancer;   Esophageal Cancer;   Otorhinolaryngologic Neoplasms;   Ear Cancer;   Nose Cancer;   Laryngeal Cancer;   Pharyngeal Cancer Intervention:   Drug: Recombinant oncolytic herpes simplex virus type 1 (R130) Sponsors:   Shanghai Yunying Medical Technology;   Eye & ENT Hospital of Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2023 Category: Research Source Type: clinical trials